

Combining Antiangiogenesis Treatment and Chemoembolization

A new approach for managing hepatocellular carcinoma.

BY ELENI LIAPI, MD, AND JEAN-FRANCOIS GESCHWIND, MD

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death behind only lung and colon cancers.¹ Eighty percent of new cases occur in developing countries, but the incidence is increasing in economically developed regions, including the United States.¹ Importantly, in the Western Hemisphere, only 30% of patients are diagnosed at an early stage and are eligible for curative therapies, such as resection or transplantation. For patients diagnosed with unresectable HCC, several nonsurgical palliative treatment options exist, including transcatheter arterial chemoembolization (TACE).² TACE exploits the preferential blood supply of liver tumors from the hepatic artery for targeted delivery of chemotherapeutic agents and embolization particles to the tumor vascular bed, while sparing the surrounding liver parenchyma.³ TACE has been shown to have a survival benefit for patients with intermediate and advanced stages of HCC.^{2,4,5}

The fundamental role of angiogenesis in tumor progression was first suggested by Hlatky et al in a classic study describing that tumors cannot grow beyond 1 or 2 mm without the formation of new blood vessels.⁶ This complex process facilitates tumor progression and eventually tumor metastatic spread.^{6,7} Several factors, including tumor hypoxia, growth factors, cytokines, oncogene activation, and other mutations interact to stimulate angiogenesis.^{7,8} Therefore, targeted inhibition of angiogenesis can be achieved at any of these levels with various treatments designed to bind growth factors with monoclonal antibodies, inhibit the downstream signaling from tyrosine kinase receptors, or disrupt the interaction between proliferating endothelial cells and matrix components.

Theoretically, after antiangiogenic treatment, the tumor vasculature may undergo morphologic changes, whereby immature blood vessels are pruned, blood vessel tortuosity and dilation decrease, and a closer association between per-

icytes and endothelial cells is induced.⁹ As a result, tumor blood vessel leakage, vascular permeability, and interstitial fluid pressure decrease. If chemotherapy is administered after antiangiogenic drug-induced vascular changes, it can be quite advantageous because it would result in increased intratumoral drug delivery as well as an increase in the number of tumor cells that are sensitive to chemotherapy. A recent study showed that there is improved penetration of the chemotherapy into the tumor upon vessel normalization.¹⁰

Until recently, there was no standard systemic therapy for unresectable HCC. The introduction of antiangiogenic therapy, such as the multikinase inhibitor sorafenib, has changed the management algorithm of patients with advanced disease.^{11,12} Because antiangiogenic drugs are generally cytostatic rather than cytotoxic, combinations involving conventional cytotoxic chemotherapies with antiangiogenesis drugs may be useful for maximizing therapeutic efficacy. Moreover, given that HCC presents as hypervascular tumor(s), combining therapies that inhibit angiogenesis on a molecular and mechanistic level seems particularly attractive. Finally, given the fact that TACE directly causes angiogenesis through activation of the hypoxia-mediated pathway (hypoxic changes in the tumor directly upregulate angiogenesis via vascular endothelial growth factor [VEGF]) thereby potentially limiting its efficacy, it was logical to combine TACE with agents that directly counteract this angiogenic activity.

The administration of antiangiogenic therapy in conjunction with locally delivered chemotherapy can help improve penetration of the chemotherapy into the tumor upon vessel normalization.¹⁰ In this article, we briefly report on preliminary studies that combine antiangiogenic therapy administered systemically with transcatheter intra-arterial chemoembolization.




Figure 1. Significant increase in the amount of tumor necrosis and decreased tumor vascularization in a 68-year-old patient who received sorafenib followed by two cycles of TACE. The patient was bridged to surgical resection 3 months after the second cycle of TACE. Axial magnetic resonance imaging (MRI) of the liver showing a 10.3-cm hypervascular HCC, located in the right hepatic lobe, with 90% enhancement (A). Selective digital subtraction angiogram of the tumor, during the first TACE procedure, demonstrating increased hypervascularity (B). Axial MRI of the liver, 3 weeks after baseline MRI (A) demonstrating now, a similarly sized tumor but with increased tumor necrosis and 30% enhancement (C). Selective digital subtraction angiogram of the tumor during the second cycle of TACE, showing minimal contrast uptake of the necrotic portion of the tumor (D).

BEVACIZUMAB AND TACE

One of the most critical and specific factors for blood vessel formation is VEGF.¹³ VEGF is an endothelial cell mitogen that regulates proliferation, permeability, and survival of endothelial cells through inhibition of apoptosis.¹³⁻¹⁵ HCC is one of the most vascular solid cancers associated with a high propensity for vascular invasion and a high expression of VEGF.^{4,16,17} Upregulation of VEGF has been correlated with increased tumor invasion, intratumoral microvessel density, disease recurrence, and poor prognosis.¹⁸⁻²⁰ One approach to inhibit angiogenesis is to use monoclonal antibodies directed at VEGF.^{21,22}

Bevacizumab is such a humanized monoclonal antibody that, through binding to VEGF, it prevents the interaction of VEGF with its receptors on the surface of endothelial cells. When unblocked, this interaction may lead to endothelial cell proliferation and new blood vessel formation.²³ VEGF expression is known to play an important role in the development of HCC, and the degree of its expression is reported to be associated with tumor size and histologic grade. Several studies have explored the potential therapeutic role for bevacizumab in patients with HCC.

The results of the first United States phase II study combining antiangiogenic therapy with TACE were

recently presented.²⁴ Tumor response and safety of concurrent bevacizumab and TACE were evaluated in 26 patients with unresectable HCC (Eastern Cooperative Oncology Group status, 0–2; Child-Pugh stages, A–B; Barcelona Clinic Liver Cancer classes, B–C). These patients received bevacizumab 10 mg/kg every 2 weeks, in addition to TACE, in a 6-week cycle (on average, 1–3 cycles). The primary endpoint was tumor response, assessed by MRI at baseline and 3 weeks after TACE, using size (Response Evaluation Criteria In Solid Tumors [RECIST] criteria) and contrast-enhancement (European Association for the Study of the Liver [EASL] criteria). Secondary endpoints included safety and survival.

On follow-up imaging, index lesions had a mean decrease in size of 13% ($P < .0005$). Using RECIST, eight (35%) patients achieved partial response, and 15 (65%) patients had stable disease. Targeted tumors showed a mean decrease in contrast enhancement of 69% ($P < .0005$). By EASL criteria, 14 (60%) patients had complete or partial response, and nine (39%) had stable disease. The disease control rate was 100% using either criteria while undergoing treatment. Median overall survival was 13.5 months, with 10 patients still alive. Fifteen (58%) patients experienced grade 3/4 toxicities possibly related to either therapy, with most toxicities resolving within 2 months of therapy. Overall, the combination therapy of bevacizumab and TACE was reasonably well tolerated in unresectable HCC patients, with a 100% disease control rate by imaging criteria and median overall survival of 13.5 months.

SORAFENIB AND TACE

The mitogen-activated protein kinase (MAPK) pathway, which includes a cascade of phosphorylation events involving multiple kinases and is vital for the transduction of cell proliferation and differentiation signals, is often dysregulated during hepatocarcinogenesis. Upregulated activity of the MAPK pathway has been well documented in HCC.^{4,11,12,25}

Sorafenib is a multikinase inhibitor that blocks tumor proliferation by targeting the Raf/MAPK/extracellular signal-regulated protein kinase signaling pathway. It also has antiangiogenic properties by targeting the tyrosine kinase VEGFR-2, VEGFR-3, and plant-derived growth factor receptor β . Sorafenib is the first systemic chemotherapy to demonstrate a survival advantage in patients with HCC and is the only approved systemic therapy for patients with intermediate stage HCC.²⁶ Combining such an agent—its oral administration makes it even more attractive—with TACE was therefore extremely appealing, especially given the additional synergy between doxorubicin (used in TACE) and sorafenib.

To that end, we conducted the first United States phase II study evaluating the safety of sorafenib combined with

transarterial chemoembolization with doxorubicin-eluting beads (DEB-TACE) in patients with unresectable HCC.²⁷ Thirty-four patients with Child-Pugh scores A to B7, Barcelona Clinic Liver Cancer classes A to C, Eastern Cooperative Oncology Group status 0 to 1, and treatment naïve, have so far been enrolled in the study and received sorafenib 400 mg twice daily 1 week before DEB-TACE, followed by DEB-TACE in 6-week cycles (sorafenib held 3 days before and after DEB-TACE in the first eight patients). Sorafenib was dosed continuously in the remaining patients. Tumor response was assessed by RECIST and EASL criteria (lack of contrast enhancement) using MRI obtained at baseline and 3 weeks after DEB-TACE and then every 1 to 2 cycles thereafter.

An interim safety assessment performed after the initial eight patients did not reveal any outstanding toxicity, with grade 3 toxicities mostly limited to hand-foot skin reaction (42%) (resolved with dose reduction), right upper quadrant pain (28%), fatigue (28%), lymphopenia (14%), and hypertension (14%). On follow-up imaging, patients who had completed DEB-TACE had 100% objective tumor response by EASL and partial response or stable disease by RECIST (Figure 1). Overall, this preliminary analysis shows that the combination appears to be safe because it did not result in any greater toxicity than with either therapy alone.

FUTURE DIRECTIONS

The rationale for combining antiangiogenic drugs with TACE is abundantly clear. If this combination is proven to be safe and found to increase time to tumor progression, it is very likely that it will become common clinical practice. The data have so far been promising. It should, however, be stressed that further research is necessary to demonstrate a clear survival benefit. This new perspective in the management of patients with unresectable HCC has opened the door for translational studies to identify potential predictive markers of response to this combination therapy and guide patient selection. By the end of 2011, we should have the results of several clinical trials that are currently underway, which will hopefully lead to a more effective treatment for this highly lethal cancer. ■

Eleni Liapi, MD, is an instructor at the Division of Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. She has disclosed that she holds no financial interest in any product or manufacturer mentioned herein.

Jean-Francois Geschwind, MD, is Professor of Radiology, Surgery and Oncology, and Director of Vascular and Interventional Radiology and the Interventional Radiology Center at Johns Hopkins University School of Medicine in Baltimore, Maryland. He has disclosed that he is a consult-

ant for Biocompatibles, Bayer HealthCare, Guerbet, and Nordion, and that he receives grant/research funding from Biocompatibles, Genentech, Bayer HealthCare, Philips Medical, Nordion, Context Vision, CeloNova, and RSNA. Dr. Geschwind may be reached at (410) 614-6597; jfg@jhmi.edu.

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. *Ann Intern Med.* 2003;139:817-823.
2. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. *J Clin Oncol.* 2007;25:978-986.
3. Liapi E, Georgiades CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. *Tech Vasc Interv Radiol.* 2007;10:2-11.
4. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology.* 2002;35:1164-1171.
5. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. *Hepatology.* 1998;27:1578-1583.
6. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. *J Natl Cancer Inst.* 2002;94:883-893.
7. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. *Nature.* 2000;407:242.
8. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer.* 2003;3:401-410.
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science.* 2005;307:58-62.
10. Escorcia FE, Henke E, McDevitt MR, et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. *Cancer Research.* 2010;70:9277-9286.
11. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. *Hepatology.* 2008;48:1312-1327.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008;359:378-390.
13. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem Biophys Res Commun.* 1989;161:851-858.
14. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol.* 2005;23:1011-1027.
15. Dvorak HF, Brown LF, Deltmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol.* 1995;146:1029-1039.
16. Schneider BP, Miller KD. Angiogenesis of breast cancer. *J Clin Oncol.* 2005;23:1782-1790.
17. Jeng KS, Sheen IS, Wang YC, et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. *World J Gastroenterol.* 2004;10:643-648.
18. Beekun WD, Fernandez A, Jousen AM, et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. *J Natl Cancer Inst.* 2001;93:382-387.
19. Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int.* 2005;4:220-226.
20. Takahashi Y, Kitada Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. *Cancer Res.* 1995;55:3964-3968.
21. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody. *Angiogenesis.* 2004;7:335-345.
22. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. *Am J Health Syst Pharm.* 2005;62:1021-1032.
23. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature.* 1993;362:841-844.
24. Reyes DK, Vossen JA, Kamel IR, et al. Phase II trial of bevacizumab combined with transarterial chemoembolization (TACE) for hepatocellular carcinoma: initial experience at two institutions. Abstract presented at: ASCO Gastrointestinal Cancers Symposium; January 2010; Orlando, FL.
25. Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. *J Clin Oncol.* 2009;27:833-835.
26. Emmenegger U, Kerbel RS. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. *Onkologie.* 2007;30:606-608.
27. Reyes DK, Azad NS, Koteish A, et al. Phase II trial of sorafenib combined with doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) for patients with unresectable hepatocellular carcinoma (HCC): Interim safety and efficacy analysis. Abstract presented at: ASCO Gastrointestinal Cancers Symposium; January 2010; Orlando, FL.

Indications for Use

The Mo.Ma Ultra Proximal Cerebral Protection Device is indicated as an embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures involving lesions of the internal carotid artery and/or the carotid bifurcation.

The reference diameter of the external carotid artery should be between 3-6 mm and the reference diameter of the common carotid artery should be between 5-13 mm.

Contraindications

The Mo.Ma Ultra Proximal Cerebral Protection Device is contraindicated for use in patients showing one of the following:

- Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated
- Patients with severe disease of the ipsilateral common carotid artery
- Inability to respond to external questions and stimuli, or to exert a pressure with the contralateral hand
- Severe peripheral vascular disease preventing femoral access, hemorrhagic or hypercoagulable status and/or inability to obtain hemostasis at the site of the femoral puncture
- Patients with severe vascular tortuosity or anatomy that would preclude the safe introduction of the Mo.Ma Ultra device, a stent system or other procedural devices
- Patients with uncorrected bleeding disorders

Warnings

- The safety and effectiveness of the Mo.Ma Ultra Proximal Cerebral Protection Device has not been demonstrated with carotid stent systems other than the ACCULINK® and RX ACCULINK® Carotid Stent, XACT® Carotid Stent, PRECISE® Carotid Stent, PROTEGE® RX Carotid Stent, and WALLSTENT® Carotid Stent.
- The safety and effectiveness of the Mo.Ma Ultra Proximal Cerebral Protection Device has not been evaluated in vasculatures other than the carotid.
- Antiplatelet and anticoagulation therapy should be administered pre- and post-procedure at a dose deemed appropriate by a physician.
- Only interventionalists who have sufficient experience should carry out carotid artery angioplasty and stenting aided by proximal flow blockage cerebral protection devices. A thorough understanding of the technical principles, clinical applications and risks associated with carotid artery angioplasty and stenting is necessary before using this product.
- The Mo.Ma Ultra Proximal Cerebral Protection Device is not recommended in patients who cannot tolerate contrast agents necessary for intraoperative imaging or who have chronic renal insufficiency.
- The Mo.Ma Ultra Proximal Cerebral Protection Device is intended for one time use only. DO NOT RESTERILIZE AND/OR REUSE, as this can potentially result in compromised device performance and increased risk of inappropriate resterilization and cross-contamination.
- Perform balloon purging as described in this Instruction for Use, before inserting the Mo.Ma Ultra Proximal Cerebral Protection Device inside the patient.
- Exercise care during handling and avoid acute bends of the device before and during the balloon purging procedure.
- Avoid positioning the Mo.Ma Ultra Proximal Cerebral Protection Device without the hollow mandrel.
- The Mo.Ma Ultra balloons should not be over-inflated.
- When inflating the occlusive balloons, inflation confirmation must be made by angiographic visual estimation of balloon cylindrical shape deformation (not by pressure).
- After inflating the two balloons immediately perform angiographic check of blood flow blockage as described in the CHECK OF FLOW BLOCKAGE section in the Instructions for Use, and check patient's clinical tolerance to occlusion.

- Should patient intolerance to occlusion occur during the procedure, immediately remove all debris performing syringe blood aspirations and deflate the proximal (CCA) balloon.
- Before deflating the two occlusion balloons always verify that no more debris is retrieved in the aspirated blood as observed in the filter basket.
- ICA lesion must not be crossed by guidewires or any other interventional catheters before the two occlusion balloons have been inflated and before having checked that blood flow has been effectively blocked.
- When the Mo.Ma Ultra Proximal Cerebral Protection Device is exposed to the vascular system, it should be manipulated while under high-quality fluoroscopic observation.
- Do not place the occlusion balloons into highly calcified vessel segments of the CCA or ECA.
- Do not manipulate the Mo.Ma Ultra Proximal Cerebral Protection Device when the occlusive balloons are inflated.
- If resistance occurs during manipulation do not force or continue to manipulate. The reason for the resistance must first be ascertained by fluoroscopy, road mapping or DSA before the Mo.Ma Ultra Proximal Cerebral Protection Device is moved backwards or forwards.
- Use only a mixture of contrast medium and saline solution (50/50) to fill the occlusion balloons. Never use air or any gaseous medium or pure contrast to inflate the occlusion balloons.
- Do not use with Lipiodol or Ethiodiol contrast media, or other such contrast media, which incorporate the components of these agents.
- Do not expose the Mo.Ma Ultra Proximal Cerebral Protection Device to organic solvents, e.g. acetone, alcohol.
- Use the Mo.Ma Ultra Proximal Cerebral Protection Device prior to the "Use By" date specified on the package.

Precautions

- Allergic reactions to contrast medium should be identified, and if possible, treated before the procedure.
- The general technical requirements for catheter insertion must be observed at all times. This includes purging the balloons, flushing the components with sterile, isotonic saline solution prior to use and the usual prophylactic, systemic heparinization.
- Confirm the compatibility of other devices (guidewires, balloon dilatation catheters, stent delivery systems, etc.) with the Mo.Ma Ultra Proximal Cerebral Protection Device before use.
- Do not use any part of the Mo.Ma Ultra Proximal Cerebral Protection Device if the package is opened or damaged.

www.medtronic.com

www.invattec.com

Medtronic Cardiovascular
3576 Unocal Place
Santa Rosa, CA 95403
USA
Tel: 707.525.0111

Product Services
Tel: 888.283.7868
Fax: 800.838.3103

**CardioVascular LifeLine
Customer Support**
Tel: 877.526.7890
Tel: 763.526.7890

